On Thursday, a committee of advisers to the Food and Drug Administration met for the second time in as many weeks to review an experimental coronavirus vaccine.
The panel last week endorsed Pfizer and BioNTech’s shot, clearing the way for the regulator to issue a historic emergency authorization the next day, and this week convened to review Moderna’s candidate.
Both vaccines were found in large trials of tens of thousands of volunteers to be strongly effective, preventing COVID-19 in nearly all participants who received them. FDA scientists affirmed the companies’ claims in their own reviews, issuing detailed analysis of Pfizer and BioNTech’s data last week and of Moderna’s this Tuesday.
